BioLineRX ADR

BioLineRx Earnings Call: Pipeline Momentum, Profit Squeeze TipRanks

BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update PR Newswire TEL AVIV, Israel, May 27, 2026 - Announced first patient dosed in Phase 1/2a clinical trial of GLIX1

BioLineRx Kicks Off GLIX1 Clinical Trial as Q1 2026 Loss Widens on Higher R&D Spend TipRanks

BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting PR Newswire TEL AVIV, Israel and OSLO, Norway, May 22, 2026 TEL AVI

BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Pat

BioLineRx doses first patient in glioblastoma drug trial Investing.com

BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) PR Newswire TEL AVIV, Israel, March 26, 2026 GLIX1, a TET2 activator , is a first -in- class ,

BioLineRx Reports 2025 Financial Results and Provides Corporate Update PR Newswire TEL AVIV, Israel, March 23, 2026 - On track to initiate Phase 1/2a clinical trial of GLIX1 for treatment of gliobl

BioLineRx to Report 2025 Annual Results on March 23, 2026 PR Newswire TEL AVIV, Israel, March 16, 2026 Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel , March 16, 2026 /PRNew

BioLineRx to Report Third Quarter 2025 Results on November 24, 2025 PR Newswire TEL AVIV, Israel, Nov. 18, 2025 Management to Hold Conference Call at 8:30 a.m. EST TEL AVIV, Israel , Nov. 18

BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types PR Newswire TEL AVIV, Israel, Nov. 17, 2025 Patent covers the use o

BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers PR Newswire TEL AVIV

BioLineRx Reports Second Quarter 2025 Financial Results and Provides Corporate Update PR Newswire TEL AVIV, Israel, Aug. 14, 2025 - Reports continued progress in the evaluation of assets for potent

BioLineRx to Report Second Quarter 2025 Results on August 14, 2025 PR Newswire TEL AVIV, Israel, Aug. 7, 2025 Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel , Aug. 7, 2

BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting PR Newswire TEL AVIV, Israel

BioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate Update PR Newswire TEL AVIV, Israel, May 27, 2025 - Reports continued progress in the evaluation of assets for potentia